Table 1.

Clinical characteristics, tumor response, and TTP

FactornOverall response percentP (Fisher's exact)Median TTP (mo)P (log-rank)
All patients56345.5
ER status
    Negative27440.164.70.96
    Positive29246.0
Hormone receptor status
    Negative23390.573.70.61
    Positive33306.0
Adjuvant chemotherapy
    No8250.709.30.79
    Yes48355.1
No. prior metastatic chemotherapy regimens
    012330.934.20.55
    127375.5
    217295.9
Anthracycline
    No15331.005.40.98
    Yes41345.9
Taxane
    No12420.526.00.45
    Yes44324.7
5-Fluorouracil
    No26351.005.10.48
    Yes30335.5
Hormone therapy
    No18331.004.20.98
    Yes38346.0
Age, y
    ≤5026351.003.70.45
    >5030336.0
Age (quartile), y
    ≤4316440.593.70.52
    43-5213315.1
    52-5813389.1
    >5814215.3
VEGF levels
    Unknown7140.537.90.01
    0-32.625409.3
    >32.624333.7
Disease sites
    Lung30430.165.90.52
    Liver30300.586.00.56
    Pleural effusion7291.003.70.24
    Bone26310.786.00.11
    Skin1
    Breast8500.424.80.83
    Lymph nodes29450.095.10.93
    Soft tissue6170.655.70.95
    Other2
Dominant metastatic site
    Visceral46351.005.90.15
    Osseous3
    Soft7293.5
No. disease sites
    11000.012.80.05
    >146415.5